Donor-Specific Nucleic Acid Detection for Transplant Rejection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring organ transplant patients for rejection are invasive, expensive, and lack sensitivity, making early detection of conditions like cardiac allograft vasculopathy difficult and costly, with significant morbidity and resource utilization.
Innovation Solution
Non-invasive methods involving genotyping of both donor and recipient to detect donor-specific nucleic acids in bodily fluids, using polymorphic markers like SNPs, and advanced sequencing techniques to monitor the presence and quantity of these markers over time, allowing for early detection of rejection and other transplant outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive surveillance procedures are used to monitor transplant rejection, then detection sensitivity may be improved, but patient morbidity and procedure complexity increase
Solution Approach 1:
The patent replaces invasive mechanical biopsy procedures with a molecular detection system that analyzes cell-free DNA in blood plasma. This substitution eliminates the need for physical tissue sampling while achieving superior detection sensitivity through genomic marker analysis, directly resolving the contradiction between detection precision and patient morbidity.
Solution Approach 2:
The patent introduces cell-free DNA in blood plasma as an intermediary biomarker that reflects the state of the transplanted organ without requiring direct contact with the organ tissue. This intermediary enables remote monitoring of graft rejection through simple blood draws, resolving the contradiction by decoupling detection sensitivity from invasive procedures.
2Reliability
If invasive biopsy procedures are performed for rejection monitoring, then transplant status can be assessed, but procedure complexity and resource utilization increase
Solution Approach 1:
The patent replaces complex surgical biopsy procedures with a molecular analysis system that detects donor-specific genomic markers in circulating cell-free DNA. This substitution maintains reliable transplant status assessment while eliminating the complexity of invasive tissue sampling, anesthesia, and surgical intervention.
Solution Approach 2:
The patent changes the measurement parameter from macroscopic tissue morphology (biopsy) to molecular genomic markers (cell-free DNA sequences). This parameter change enables reliable transplant monitoring through simple blood tests, dramatically reducing procedure complexity while maintaining or improving assessment reliability.
3Reliability
If traditional surveillance methods are used for rejection detection, then monitoring can be performed, but cost and time resources are excessive
Solution Approach 1:
The patent performs preliminary genotyping of both donor and recipient before transplantation to establish a reference profile of donor-specific polymorphic markers. This preliminary action enables rapid, targeted detection of rejection events during follow-up by simply monitoring for the presence or absence of these pre-identified markers in cell-free DNA, significantly reducing monitoring time while maintaining high reliability.
Solution Approach 2:
The patent changes the monitoring approach from broad, non-specific tests to targeted detection of specific donor polymorphic markers. This parameter change allows for rapid, efficient rejection detection by focusing only on donor-specific genomic sequences, reducing both time and resource requirements while improving detection reliability.
Data Source
AI summary
The invention provides methods, devices, compositions and kits for diagnosing or predicting transplant status or outcome in a subject who has received a transplant.